G
78.77
1.36 (1.76%)
| 前收盘价格 | 77.40 |
| 收盘价格 | 77.37 |
| 成交量 | 246,092 |
| 平均成交量 (3个月) | 628,309 |
| 市值 | 2,163,784,704 |
| 价格/销量 (P/S) | 7.65 |
| 股市价格/股市净资产 (P/B) | 10.39 |
| 52周波幅 | |
| 利润日期 | 18 Feb 2025 - 24 Feb 2025 |
| 营业毛利率 | -31.25% |
| 营业利益率 (TTM) | -10.11% |
| 稀释每股收益 (EPS TTM) | -3.09 |
| 季度收入增长率 (YOY) | 44.20% |
| 总债务/股东权益 (D/E MRQ) | 56.77% |
| 流动比率 (MRQ) | 2.40 |
| 营业现金流 (OCF TTM) | -55.17 M |
| 杠杆自由现金流 (LFCF TTM) | -20.06 M |
| 资产报酬率 (ROA TTM) | -8.27% |
| 股东权益报酬率 (ROE TTM) | -36.40% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Health Information Services (US) | 混合的 | 看跌 |
| Health Information Services (全球的) | 混合的 | 看跌 | |
| 股票 | GeneDx Holdings Corp. | 看涨 | 看涨 |
AIStockmoo 评分
-1.1
| 分析师共识 | -1.5 |
| 内部交易活动 | -1.5 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.10 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics. |
|
| 部门 | Healthcare |
| 行业 | Health Information Services |
| 投资方式 | Small Growth |
| 内部持股比例 | 18.19% |
| 机构持股比例 | 72.00% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Casdin Capital, Llc | 30 Sep 2024 | 3,507,164 |
| Corvex Management Lp | 30 Sep 2024 | 2,473,781 |
| Oracle Investment Management Inc | 30 Sep 2024 | 1,045,768 |
| Gagnon Securities Llc | 30 Sep 2024 | 541,943 |
| Fred Alger Management, Llc | 30 Sep 2024 | 394,230 |
| Point72 Asset Management, L.P. | 30 Sep 2024 | 293,671 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 95.00 (Craig-Hallum, 20.61%) | 购买 |
| 中 | 75.00 (-4.78%) | |
| 低 | 70.00 (Goldman Sachs, -11.13%) | 保留 |
| 平均值 | 80.00 (1.57%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 83.20 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Craig-Hallum | 30 Oct 2024 | 95.00 (20.61%) | 购买 | 83.20 |
| 24 Oct 2024 | 70.00 (-11.13%) | 购买 | 59.09 | |
| Goldman Sachs | 30 Oct 2024 | 70.00 (-11.13%) | 保留 | 83.20 |
| 16 Oct 2024 | 54.00 (-31.44%) | 保留 | 60.78 | |
| Wells Fargo | 30 Oct 2024 | 75.00 (-4.78%) | 保留 | 83.20 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FEELEY KEVIN | - | 80.50 | -3,728 | -300,104 |
| STUELAND KATHERINE | - | 80.50 | -10,501 | -845,331 |
| 累积净数量 | -14,229 | |||
| 累积净值 ($) | -1,145,435 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 80.50 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| FEELEY KEVIN | 职员 | 16 Dec 2024 | 卖 (-) | 3,728 | 80.50 | 300,104 |
| FEELEY KEVIN | 职员 | 16 Dec 2024 | 执行期权 | 7,197 | - | - |
| STUELAND KATHERINE | 职员 | 16 Dec 2024 | 卖 (-) | 10,501 | 80.50 | 845,331 |
| STUELAND KATHERINE | 职员 | 16 Dec 2024 | 执行期权 | 18,750 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合